FDA Approves Supplemental Application for PERSERIS Kit by INDIVIOR
The FDA has approved a supplemental application for the PERSERIS Kit, which contains risperidone.
Published: July 11, 2026
Updated: July 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / Antipsychotic
Asset: INDIVIOR
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
INDIVIOR
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of the supplemental application for the PERSERIS Kit is significant as it strengthens INDIVIOR's competitive position in the antipsychotic market. This approval may lead to increased market share and necessitates strategic responses from competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for market uptake and any competitive responses from other antipsychotic manufacturers.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.